Patients with promoter methylation survived longer after temozolomide plus radiotherapy treatment compared to patients with unmethylated MGMT. Similarly, MGMT hypermethylation was observed in gliomas from patients who had survived longer after treatment with the alkylating agent carmustine [160]. Here, MGMT is linked to central nervous system cancer.